- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SNY
Recent news which mentions SNY
From Benzinga
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
July 10, 2023
From Benzinga
From Benzinga
First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California
July 03, 2023
From Benzinga
GSK Confidentially Settles First Zantac-Associated Cancer Lawsuit Due For US Trial Next Month
June 23, 2023
From Benzinga
Virgin Galactic shares tumble, while Trupanian and GSK climb and other stocks on the move
June 23, 2023
From MarketWatch
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
June 22, 2023
From Benzinga
From Benzinga
2 Biopharma Stocks Making Big Moves Tuesday
June 20, 2023
From Motley Fool
Sanofi Stock Is Trading Higher Today - Here's Why
June 20, 2023
From Benzinga
2 Best Biotech Stocks to Buy Right Now
June 16, 2023
From Motley Fool
From Benzinga
From Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
June 09, 2023
From Benzinga
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
From Motley Fool
The 7 Most Reliable Dividend Stocks to Buy Now
June 06, 2023
From InvestorPlace
From MarketWatch
3 Biotech Stocks to Avoid Like the Plague
May 23, 2023
From InvestorPlace
From Benzinga
2 Bear Market Defying Stocks to Buy in May
May 22, 2023
From Motley Fool
From MarketWatch
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
May 17, 2023
From Benzinga
From InvestorPlace
Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing
May 12, 2023
From Benzinga
From Benzinga
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.